Acorda Therapeutics (NASDAQ:ACOR) Earns Buy Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a report published on Saturday morning. The firm issued a buy rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Trading Down 24.9 %

Shares of Acorda Therapeutics stock opened at $0.66 on Friday. The company’s fifty day simple moving average is $11.42 and its 200-day simple moving average is $12.26. The stock has a market capitalization of $819,640.00, a PE ratio of 0.00 and a beta of 1.40. Acorda Therapeutics has a 1-year low of $0.61 and a 1-year high of $24.20. The company has a debt-to-equity ratio of 3.07, a current ratio of 0.33 and a quick ratio of 0.26.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.